Hunan Jiudian Pharmaceutical Co Ltd
SZSE:300705
Hunan Jiudian Pharmaceutical Co Ltd
PP&E Net
Hunan Jiudian Pharmaceutical Co Ltd
PP&E Net Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | PP&E Net | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Hunan Jiudian Pharmaceutical Co Ltd
SZSE:300705
|
PP&E Net
¥1.2B
|
CAGR 3-Years
28%
|
CAGR 5-Years
20%
|
CAGR 10-Years
N/A
|
|
|
H
|
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
|
PP&E Net
¥3.3B
|
CAGR 3-Years
-3%
|
CAGR 5-Years
9%
|
CAGR 10-Years
N/A
|
|
|
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
|
PP&E Net
¥697.2m
|
CAGR 3-Years
20%
|
CAGR 5-Years
23%
|
CAGR 10-Years
9%
|
|
|
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
|
PP&E Net
¥7.4B
|
CAGR 3-Years
6%
|
CAGR 5-Years
13%
|
CAGR 10-Years
16%
|
|
|
C
|
CSPC Innovation Pharmaceutical Co Ltd
SZSE:300765
|
PP&E Net
¥2.5B
|
CAGR 3-Years
59%
|
CAGR 5-Years
30%
|
CAGR 10-Years
N/A
|
|
|
S
|
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
|
PP&E Net
¥573.1m
|
CAGR 3-Years
12%
|
CAGR 5-Years
10%
|
CAGR 10-Years
N/A
|
|
Hunan Jiudian Pharmaceutical Co Ltd
Glance View
Hunan Jiudian Pharmaceutical Co Ltd, nestled amidst the vibrant commercial landscape of China, exemplifies the dynamic evolution of the pharmaceutical industry within the region. Founded on the principles of innovation and resilience, the company has carved a niche by focusing on the development, production, and sale of a variety of active pharmaceutical ingredients (APIs) and finished dosage formulations. It operates through an intricate web of research and development that is deeply aligned with the latest advancements in medical science. Central to its operations is a robust R&D facility that not only ensures high-standard quality control but also keeps the pipeline brimming with potential new products. This forward-thinking approach is critical, as it continually feeds the market with pharmaceuticals that cater to both chronic and acute health conditions, ranging from anti-infectives to cardiovascular drugs. The company capitalizes on a vertically integrated business model, which substantially aids in controlling cost and quality across all stages of production. By managing a seamless supply chain that extends from raw material procurement to drug distribution, Hunan Jiudian Pharmaceutical ensures both operational efficiency and market competitiveness. Revenue streams largely flow from the sale of its proprietary products in domestic and international markets, supported by a comprehensive marketing strategy and a broad distribution network. This pragmatic blend of science, strategy, and salesmanship allows the company not only to generate profits but also to contribute significantly to the global pharmaceutical framework, marking its presence as a formidable player in this ever-changing industry.
See Also
What is Hunan Jiudian Pharmaceutical Co Ltd's PP&E Net?
PP&E Net
1.2B
CNY
Based on the financial report for Sep 30, 2024, Hunan Jiudian Pharmaceutical Co Ltd's PP&E Net amounts to 1.2B CNY.
What is Hunan Jiudian Pharmaceutical Co Ltd's PP&E Net growth rate?
PP&E Net CAGR 5Y
20%
Over the last year, the PP&E Net growth was 17%. The average annual PP&E Net growth rates for Hunan Jiudian Pharmaceutical Co Ltd have been 28% over the past three years , 20% over the past five years .
You don't have any saved screeners yet